Submitting Continuous Glucose Monitoring Data in Clinical Trials

Issue Date: May 6, 2026
Issued by: Center for Drug Evaluation and Research
Topic(s):
Status: Final

Submitting Continuous Glucose Monitoring Data in Clinical Trials

This document provides technical specifications for submitting continuous glucose monitoring (CGM) data in clinical trials to support a marketing application for a drug or biological product. In general, FDA’s guidance documents do not establish legally enforceable responsibilities.

Download the Guidance Document

webmaster2026-08-05T18:55:40+00:00

ABOUT US

Avance Biosciences is a leading Contract Research Organization (CRO) and Contract Testing Organization (CTO) providing CGMP and GLP-compliant analytical and bioanalytical services to support drug development. From early discovery through clinical development and commercialization, we provide CGMP and GLP-compliant services tailored to your therapeutic modality and regulatory needs.